Palmitoylethanolamide co-micronised (m-PEA)

Tier 2 — promising · Chronic pain · Fibromyalgia · Neuropathic pain

Co-micronised PEA with luteolin activates natural pain-resolving pathways without receptor desensitisation. A 2024 review of 16 trials found it significantly reduces neuropathic pain, sciatica, and fibromyalgia. Entirely free of drug interactions. The co-micronised form is essential — standard PEA absorbs poorly.

Dose: 300–600 mg/day co-micronised PEA with luteolin (Normast or equivalent); allow 6–8 weeks for effect